Latest Breaking News On - Lifeline ventures - Page 1 : comparemela.com

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiAkseli hemminkiAino kalervoDaniel goochMerck co incMerck kgaAmerican society of clinical oncologyUs department of defenseUniversity of helsinkiMerck sharp dohmeHealth affairsMerck kgaaEuropean innovation councilDepartment of defenseScius communications

Maria 01 rolls out ambitious pan-Europe startup plan

Maria 01 rolls out ambitious pan-Europe startup plan
computerweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from computerweekly.com Daily Mail and Mail on Sunday newspapers.

Eteläuomen läiJosefiina kotilainenSarita runebergFinnish business angels network fiNational strategy of technology developmentFinnish startup communityFinnish venture capital associationFinnish startup foundationHelsinki based mariaNational strategyTechnology developmentFinnish business angels networkWave venturesImpact reportLifeline venturesVoima ventures

Finnish startups face funding dip, but domestic venture capital flourishes amid economic uncertainty

In 2023, Finnish startups experienced a significant reduction in funding, down from the previous year s record highs, reflecting a broader trend of economic slowdown affecting startup investments across Europe and the United States. According to the Finnish Venture Capital Association (FVCA), total growth funding for Finnish startups was approximately €871 million, a sharp decline from the €1.7 billion raised in 2022.

Jussi sainiemiJonne kuittinenVenture capital committeeLifeline venturesGreencode venturesFailup venturesDeputy managing partnerVoima venturesCapital committeeDeputy chief executive

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS

Eteläuomen läiUnited statesAkseli hemminkiAino kalervoDaniel goochUs department of defenseMerck kgaaMerck co incMerck sharp dohmeEuropean innovation councilUniversity of helsinkiAmerican association for cancer researchScius communicationsMerck kgaResults reveal mechanismCorrelative analyses

The hottest of Helsinki - 10 startups to watch out this year

Helsinki is one of the hottest startup hubs in the world, growing numerous successful startups to watch out for in 2024.

Eteläuomen läiJuha pekka pitkAki jarvilehtoAnna lappalainenJonne bovellVerneri jaamuruMiikka huttunenDavid helgasonAnatoly sharifulinMiika huttunenEemil visakorpiEugene kruglovAntti sartanenOhto pentikLauri tuominenAnttoni aniebonam